 II. Progression free survival PFS. III. Overall survival OS. IV. Duration of MRD-negative disease. V. Safety and tolerability of experimental arm ixazomib citrate, lenalidomide, and low dose dexamethasone IRd vs. control arm lenalidomide Rd. 